-
BB-1709 for injection was approved for clinical practice
The application for BB-1709 IND, an innovative drug of Bristiscon anti-tumor ADC, was approved by the State Food and Drug Administration of China.
2023-01-29 14:54 -
BeiGene's zebratinib was approved for clinical trials
Two global Phase 3 trials demonstrated efficacy in BRUKINSA ® (zebratinib) in first-line treatment and in adults with relapsed/refractory chronic lym...
2023-01-29 14:53 -
Hutchison Pharma announced that it has entered into a license agreement with Takeda Pharmaceutical f...
Hutchison will receive a down payment of US$400 million.
2023-01-29 14:52 -
The treatment population of 'mabaloxavir' has expanded, and how much has the global anti-influenza d...
The latest progress of mabaloxavir
2023-01-28 17:52 -
-
2022 inventory: those license-out of 'borrowing ships to go to sea'
With the rapid development of China's medicine, domestic pharmaceutical companies have gradually had fierce competition and serious involvement.
2023-01-28 17:50 -
2022 inventory: The market value of A-share CXO lost 300 billion, and only 6 stock prices achieved p...
19 companies fell, accounting for 76%, with an average decline of more than 37%.
2023-01-28 17:49 -
Annual inventory: 19 drugs were rejected by the FDA in 2022; Involving Merck, Gilead, Cinda...
Seeking new hope from failure.
2023-01-28 17:47 -
Synthetic lethal' emerging target - PRMT5 development geometry?
The research on PRMT5 small molecule inhibitors has become a hot spot in the research and development of anti-tumor drugs.
2023-01-28 17:46 -
Hot News
- BASF’s Big Restructuring: Cut... Sep 01, 2025
- Covestro and Wanhua Reshape Gl... Aug 20, 2025
- DuPont Bids Farewell to Its Ar... Sep 02, 2025
- Glenmark Recalls Over 110000 B... Aug 24, 2025
- FDA Clears Sanofi’s Wayrilz (... Aug 31, 2025
Related Products
Related Producers
